Abstracts tagged "glucocorticoids"

Abstract Number: 2367 • 2017 ACR/ARHP Annual Meeting
The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis: a Systematic Review and Meta-Analysis
Anne-Birgitte Blavnsfeldt^1,2, Malissa Dawn Thomsen³, Simon Tarp⁴, Bente Langdahl^2,5, Ellen-Margrethe Hauge^2,6 and Annette de Thurah^7,8, ¹Rheumatology, Aarhus Universityhospital, Aarhus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark, ³Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ⁴The Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark, ⁵Endocrinology, Aarhus University Hospital, Aarhus, Denmark, ⁶Aarhus Universityhospital, Aarhus C, Denmark, ⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: The role of glucocorticoids (GCs) in the treatment of rheumatoid arthritis (RA) is widely debated. GCs stimulate bone resorption and impair bone formation. Inflammatory…
Abstract Number: 2654 • 2017 ACR/ARHP Annual Meeting
Treatment-Associated DNA Methylation Patterns in Systemic Lupus Erythematosus
Juliana Imgenberg-Kreuz^1,2, Jonas Carlsson Almlöf¹, Dag Leonard³, Gunnel Nordmark², Maija-Leena Eloranta³, Leonid Padyukov⁴, Iva Gunnarsson⁴, Elisabet Svenungsson⁴, Christopher Sjöwall⁵, Lars Rönnblom², Ann-Christine Syvänen¹ and Johanna K Sandling^1,2, ¹Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ³Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ⁴Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden
Background/Purpose: DNA methylation has emerged as an important contributing factor in the pathogenesis of systemic lupus erythematosus (SLE). SLE typically requires continuous treatment to control…
Abstract Number: 212 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Large Vessel Arteritis (Giant Cell Arteritis and Temporal Arteritis): Findings from a Large Contemporaneous Real-World Cohort in the US
Zhaohui Su¹, Vandana Menon¹, Richard Gliklich² and Tom Brecht¹, ¹Research, OM1, Inc, Cambridge, MA, ²OM1, Inc, Cambridge, MA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis with annual incidence as high as 27 per 100,000 in persons…
Abstract Number: 350 • 2016 ACR/ARHP Annual Meeting
Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis
Linda Rasch¹, Lilian van Tuyl¹, Martijn Kremer², Irene E.M. Bultink², Maarten Boers^3,4 and Willem F. Lems^1,4, ¹Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Recently, we showed that treatment with COBRA-light therapy including prednisone with initially 30 mg/day, was as effective as the original COBRA scheme, with initially…
Abstract Number: 412 • 2016 ACR/ARHP Annual Meeting
Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder
Daniel B. Horton¹, Fenglong Xie², Lang Chen², Melissa Mannion³, Brian L. Strom^4,5, Jeffrey Curtis⁶ and Timothy Beukelman⁷, ¹Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Diabetes mellitus (DM) and hypertension (HTN) are well-known toxicities of glucocorticoids (GCs), but the risks of these complications are unclear in children with JIA.…
Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Rachel Black¹, Susan M. Goodman², Carlee Ruediger³, Susan Lester⁴, Sarah Mackie⁵ and Catherine Hill³, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Medicine, Hospital for Special Surgery, New York, NY, ³Medicine, The University of Adelaide, Adelaide, Australia, ⁴Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
Abstract Number: 794 • 2016 ACR/ARHP Annual Meeting
Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
Zahi Touma¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: It is challenging to describe disease activity in SLE in the context of multiple levels of glucocorticoids (GC) treatment. We aim to develop and…
Abstract Number: 977 • 2016 ACR/ARHP Annual Meeting
Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study
Maxime Samson¹, Hervé Devilliers², Kim Heang Ly³, Francois Maurier⁴, Boris Bienvenu⁵, Benjamin Terrier⁶, Pierre Charles⁷, Jean-François Besancenot², Anne-Laure Fauchais⁸, Christine Binquet⁹, Sylvain Audia¹⁰ and Bernard Bonnotte¹, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Internal Medicine, University Hospital of Limoges, Limoges, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Caen University Hospital, Caen, France, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁸Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁹INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis usually treated with glucocorticoids (GC). GC are effective but responsible for substantial morbidity and mortality. Tocilizumab…
Abstract Number: 1123 • 2016 ACR/ARHP Annual Meeting
Targeted Mutations Identify the Active Site of Glucocorticoid-Induced Leucine Zipper (GILZ)
Huapeng Fan¹, Die Wang², Qiang Cheng³, James Harris³, Sarah Jones³, Yuan Hang Yang⁴ and Eric Morand⁴, ¹Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Calyton, Australia, ²Hudson Institute of Medical Research, Clayton, Australia, ³Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia, ⁴Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) have been used to treat inflammatory disease for more than six decades, but the broad spectrum of therapeutic effects is accompanied by…
Abstract Number: 1646 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies
Roy Fleischmann¹, Jürgen Wollenhaupt², Stanley Cohen¹, Michael Weinblatt³, Lisy Wang⁴, Haiyun Fan⁵, John Andrews⁶, Liza Takiya⁵ and Eustratios Bananis⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Brigham and Women’s Hospital, Boston, MA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a post-hoc analysis of the tofacitinib RA long-term extension (LTE) studies,…
Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Matthew D. Cascino¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁶, Cees G.M. Kallenberg⁷, E. William St Clair⁸, Paul A. Monach⁹, John H. Stone¹⁰ and Paul Brunetta¹¹, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Mayo Clinic, Rochester, MN, ³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Duke University Medical Center, Durham, NC, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Genentech, Inc., South San Francisco, CA
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…
Abstract Number: 1973 • 2016 ACR/ARHP Annual Meeting
Intramuscular Versus Ultrasound Guided Peritendinous Glucocorticoid Injection for Tenosynovitis in Patients with Rheumatoid Arthritis – a Randomised, Double-Blind, Controlled Study
Mads Ammitzbøll-Danielsen^1,2, Mikkel Ostergaard^2,3, Viktoria Fana⁴, Daniel Glinatsi^2,5, Uffe Møller Døhn⁶, Lykke Midtbøll Ørnbjerg⁷, Esperanza Naredo⁸ and Lene Terslev⁶, ¹Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁵Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain
Background/Purpose: The aim of this study was to compare the efficacy of intramuscular versus ultrasound (US)-guided peritendinous glucocorticoid injection in providing disease control after…
Abstract Number: 2477 • 2016 ACR/ARHP Annual Meeting
Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
SA Bergstra¹, CF Allaart¹, R van den Berg¹, A Chopra², N Govind³, MJ Santos⁴, TWJ Huizinga⁵ and RBM Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Center for Rheumatic Diseases, Pune, India, Pune, India, ³Department of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa, ⁴Rheumatology, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ⁷Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) for newly diagnosed rheumatoid…
Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting
Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
Frank Buttgereit¹, Jonna Amann², Friederike Breitenfeldt³, Dörte Huscher⁴, Johannes WJ Bijlsma⁵ and Johannes WG Jacobs⁶, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ⁵ARC, Amsterdam, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…
Abstract Number: 2555 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Katerina Chatzidionysiou¹, Sharzad Emamikia², Jackie L. Nam³, Sofia Ramiro⁴, Josef Smolen⁵, Désirée van der Heijde⁶, Maxime Dougados⁷, Johannes WJ Bijlsma⁸, Gerd Burmester⁹, Marieke Scholte-Voshaar¹⁰, Ronald van Vollenhoven^11,12 and Robert Landewé¹³, ¹Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Paris Descartes University, Paris, France, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité University Hospital, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ¹³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].